What does ISO 10993-5 cytotoxicity testing mean in practice?
Cytotoxicity according to ISO 10993-5 is the earliest and most fundamental biological safety indicator within the ISO 10993 testing strategy. It addresses whether materials, additives or leachables from a device cause acute damaging effects on eukaryotic cells. Key endpoints include cell viability, metabolic activity and morphological changes that reveal stress or injury at the cellular level.
Testing is typically performed using established in-vitro assays such as MTT, XTT, WST-1 or NRU, which provide quantitative information on metabolic activity or membrane integrity. Qualitative morphology scoring adds important context, as early stress responses – such as rounding, shrinkage or detachment – can occur before a clear reduction in viability is measurable. Together, these endpoints provide a comprehensive picture of how the test article interacts with cells.
A viability reduction greater than 30 % compared with the negative control is widely recognized as the threshold for a cytotoxic effect under ISO 10993-5. Exceeding this cut-off requires toxicological interpretation and may trigger additional testing, for example under ISO 10993-10 (sensitization) or ISO 10993-23 (irritation). Cytotoxicity results are then integrated into the ISO 10993-1 Biological Evaluation, where they influence the overall risk assessment and further test planning.
Sample preparation and extraction follow ISO 10993-12 in order to simulate clinically relevant exposure. Risk-based selection of media (polar/non-polar), time–temperature profiles and surface-to-volume ratios is crucial for generating meaningful, regulator-accepted data that can be used directly in toxicological assessments.
Norm criteria – at a glance
| Norm criterion | Requirement / content | Note |
|---|---|---|
| Primary endpoint | Cell viability (MTT/XTT/WST/NRU) | Quantitative vs. negative control |
| Acceptance criterion | >30% viability reduction = cytotoxic effect | Often reflected as <70% viability |
| Qualitative readout | Morphology scoring/elution | Additional stress signal |
| Extraction | ISO 10993-12 aligned; polar & non-polar | Time/temperature risk-based |
| Use of data | Early decision marker | Input to ISO 10993-1 and test planning |
How we test your medical device – step by step
- Request a quote by phone or online. Key inputs: device, materials/components, contact type and exposure duration, and the device condition (e.g., sterilized/reprocessed).
- Send your device after accepting the quote. Please provide the sample in the marketed/used state where possible (including reprocessed state if applicable).
- Upon receipt, we start testing and document sample logistics and—where relevant—ISO 10993-12 aligned preparation/extraction parameters.
- We perform ISO 10993-5 cytotoxicity testing—typically using MTT/XTT/WST/NRU assays and, where appropriate, morphology scoring. The outcome is an early decision marker for your test strategy.
- You receive a digital, QES-signed report with professional interpretation. Upon request, we coordinate next steps through external toxicology (ISO 10993-17) and the ISO 10993-1 Biological Evaluation.
Why HygCen?
- DAkkS accredited testing laboratory (DIN EN ISO/IEC 17025) with GLP-compliant processes.
- Risk-based study design aligned with intended contact type, duration and use.
- Testing in the original state, including relevant processing/sterilization/reprocessing influences.
- Digital, QES-signed report with expert interpretation for MDR technical documentation.
- One-stop coordination: we manage interfaces to independent toxicologists for ISO 10993-17 and the ISO 10993-1 Biological Evaluation when needed.
For ISO 10993-5 cytotoxicity testing, colorimetric and fluorometric viability assays such as MTT, XTT, WST-1 or NRU are commonly used. These methods quantify metabolic activity or membrane integrity and provide robust quantitative endpoints relative to a negative control. In many cases, qualitative morphology scoring is added to detect early stress responses that may not yet be visible in viability data alone. The choice of assay and combination depends on the device material, matrix and extraction conditions so that the study design reflects the specific risk profile.
A viability reduction of more than 30 % versus the negative control is the established trigger for a cytotoxic effect under ISO 10993-5. This threshold supports consistent interpretation of results across laboratories and studies and clearly separates non-reactive from reactive responses. If the cut-off is exceeded, findings must be evaluated by toxicology experts and considered in the overall risk assessment. Often, this leads to additional testing or process review to clarify the impact on patient safety.
Morphology scoring provides qualitative information on structural cell changes such as rounding, shrinkage, vacuolisation or detachment from the culture surface. These features can indicate early or subtle stress that precedes measurable loss of viability. By combining morphology with quantitative viability data, sponsors obtain a more nuanced understanding of cellular responses to the test article. This is particularly valuable for borderline cases, where morphology can help differentiate between minor and clinically relevant effects.
Repeat cytotoxicity testing is recommended whenever relevant changes occur in materials, additives, manufacturing processes, sterilization or reprocessing procedures or extraction parameters. New insights from chemical characterization under ISO 10993-18 can also justify re-testing to ensure that the current worst-case scenario is adequately represented. Proactive re-evaluation helps maintain an up-to-date Biological Evaluation and supports robust MDR documentation.
Cytotoxicity data are the first biological safety signal within the ISO 10993 framework and strongly influence subsequent testing decisions. A non-cytotoxic outcome supports the assumption that the device does not cause acute cell damage under intended use conditions. If cytotoxic effects are observed, they must be interpreted in the context of exposure, other biological endpoints and chemical data as part of the ISO 10993-1 Biological Evaluation. This integrated view guides further testing, potential design modifications and risk mitigation measures.
Related links
ISO 10993-12 – Sample preparation & reference materials, ISO 10993-18 – Chemical characterization, ISO 10993-10 – Skin sensitization, ISO 10993-23 – Irritation, ISO 10993-3 – Genotoxicity, ISO 10993-4 – Hemocompatibility, Pyrogenicity & endotoxin – incl. ISO 10993-11 coordination, ISO 10993-1 – Biological Evaluation